Fast Five Quiz: Test Your Knowledge of the Diagnosis and Treatment of Locally Advanced, Unresectable Pancreatic Cancer

Michael J. Pishvaian, MD, PhD


September 26, 2018

Chemoradiotherapy (CRT) or stereotactic body radiotherapy (SBRT) may be offered to patients with local progression but no metastases, provided they have a performance status of 2 or less and a favorable comorbidity profile.

CRT or SBRT may be offered to patients who have responded to an initial 6 months of chemotherapy or have stable disease, have developed unacceptable chemotherapy-related toxicities, or have a decline in performance status as a consequences of chemotherapy toxicity. If patients respond or their disease has at least stabilized after 6 months of induction chemotherapy, CRT or SBRT may be offered as an alternative to continuing chemotherapy alone. SBRT may be offered even though evidence supporting SBRT is not robust.

For more information on CRT and SBRT in locally advanced pancreatic cancer, read here and here.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.